**Thursday 27 April 2017**

**13:00    Registration**

**13:25    Welcome and Introductory Remarks**
by President, Royal College of Physicians of Edinburgh

## Session 1 - Glomerular disease - keep it renal

Chair: Dr Emily McQuarrie, Consultant Nephrologist, Queen Elizabeth University Hospital, Glasgow

**13:30    Glomerular disease - clinico-pathological cases**
Dr Shana Coley, Clinical Senior Lecturer & Honorary Consultant Renal Pathologist, University of Glasgow
Case 1: Crescentic IgA nephropathy
Case 2: Focal segmental glomerulosclerosis in pregnancy

**14:00    An update on IgA nephropathy**
Professor Jonathan Barratt, Professor of Renal Medicine, University of Leicester
* review of recent trials examining immunosuppression for IgAN * eculizumab for IgAN?  * is there a role for fish oil/tonsillectomy?

**14:30    Targeting B cells in the management of glomerulonephritis**
Professor Lorraine Harper, Professor of Nephrology, University of Birmingham
* emerging evidence for rituximab in primary glomerulonephritides *post-transplant recurrence * novel agents (alternate Anti-CD20 drugs, B-cell activating factor inhibitors)

**15:00    Coffee / Tea**

## Session 2 - Current challenges in renal transplantation

Chair: Dr Paul Phelan, Consultant Nephrologist, Royal Infirmary, Edinburgh

**15:30    Assessment of immunological risk in kidney transplantation**
Dr Nick Torpey, Clinical Director of Transplant Services, Addenbrooke's Hospital, Cambridge
* how do we assess immunological risk in the modern era? * is an era of personalized immunosuppression emerging? * induction (needed for all/what agent/how much?)

**16:00    JAMES LIND LECTURE**
Chair: President, Royal College of Physicians of Edinburgh
**Desensitization:  transplanting the un-transplantable**
Professor Robert Montgomery, Director of Transplant Institute, New York University, USA
* outcomes from transplanting highly sensitized recipients * balancing risk between desensitization/ paired exchange/remaining on dialysis * conditioning regimens for HLA incompatible recipients

**16:45    Hi - Tea**

## Session 3 - An update on diabetic kidney disease

Chair: Dr Nicola Joss, Consultant Nephrologist, Raigmore Hospital, Inverness

**17:30**   **What can basic science tell us about diabetic kidney disease?**
Dr Bryan Conway, Senior Lecturer in Nephrology, University of Edinburgh
* what are the mechanisms by which diabetes causes kidney disease? * do animal models help the clinical treatment of
patients with kidney disease? * how do we know which patients with diabetes will get progressive chronic kidney
disease? * does basic science promise any new treatment strategies in diabetic kidney disease?

**18:00**   **How have recent trials informed the management of diabetic kidney disease?**
Professor Hiddo Lambers Heerspink, Clinical Pharmacologist, University of Groningen, The
Netherlands
* what are the clinically important recent clinical trials in diabetic kidney disease? * which patients are likely to benefit
from new therapies? * how do new agents for diabetic kidney disease compare to current 'best' practice?

**18:30**   **What does a nephrologist need to know about new  treatments for type 2 diabetes?**
Dr Alan Jaap, Consultant Diabetologist, Royal Infirmary, Edinburgh
* what is the most appropriate strategy to glycaemic control in patients with diabetic kidney impairment? * do strategies
for glycaemic control change as kidney function declines? * the approach to glycaemia in dialysis patients * how do
diabetologists view post?transplant diabetes mellitus?

**19:00**   **Coffee / Tea**

## Session 4 - Acute kidney injury for the non-nephrologist

Chair: Dr Samira Bell, Consultant Nephrologist, Ninewells Hospital, Dundee

**19:30**   **Paraproteins causing kidney disease**
Professor Chris Winearls, Associate Professor of Medicine and Consultant Nephrologist,
Oxford
* paraproteins and kidney disease ? what, why, how? * light chain deposition disease (LCDD),
*cast nephropathy

**20:00**   **What does big data tell us about acute kidney injury?**
Dr Laurie Tomlinson, Wellcome Intermediate Fellow, London School of Hygience and
Tropical Medicine
* how common is AKI in the community and does it matter? * are blockers of the renin angiotensin system really to
blame for AKI? * does big data tell us that sick day rules are a good thing?

**20:30**   **Discussion and close**